New radiation approach targets tough pancreatic tumors
NCT ID NCT03505229
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests stereotactic body radiotherapy (SBRT), a precise, high-dose radiation given over 2 weeks, for people with high-risk localized pancreatic cancer. The goal is to see if it can stop the tumor from growing locally for at least 12 months. The trial includes 30 participants who have already had or will have chemotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Stereotactic body radiotherapy (SBRT)
- What this could lead to
- If successful, SBRT could offer a more precise, shorter radiation option to control pancreatic cancer locally, potentially improving outcomes for patients with high-risk disease.
- What could go wrong
- This is a small, early-phase study (30 people) with no control group, so results may not apply broadly. SBRT also carries risks of radiation side effects to nearby organs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH RISK LOCALISED PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Royal North Shore Hospital
St Leonards, New South Wales, 2065, Australia